Thrombolex
Thrombolex innovates efficient endovascular catheters for precise, cost-effective treatment of A+VTE conditions since 2016.
Thrombolex innovates efficient endovascular catheters for precise, cost-effective treatment of A+VTE conditions since 2016.
Founded in 2016, Thrombolex designs, develops, manufactures, and distributes innovative endovascular catheters aimed at treating arterial and venous thromboembolic (A+VTE) conditions. The company's mission is to enhance patient care by creating catheters that allow for the precise infusion of physician-specified fluids, including thrombolytics, into targeted areas of the peripheral vasculature. This approach aims to treat thrombus more efficiently, in less time, and with lower doses. Their product line includes the BASHIR™ Endovascular Catheter series.
Thrombolex has garnered attention for its sophisticated catheter technology, which offers ease of placement and shorter procedure times. Notable affiliated individuals include experienced medical professionals and industry experts who contribute to the company’s innovative edge. The company has achieved significant milestones in clinical efficacy and safety, making a notable impact on the treatment of thromboembolic conditions. Their advancements have positioned them as a key player in the endovascular device market.
Companies similar to Thrombolex include Embolx, Advanced Catheter Therapies, Endovascular Engineering and NeuRx Medical.
Thrombolex was founded in 2016.
Thrombolex's headquarters is located in Doylestown, PA, US.
Thrombolex's most recent funding round was for $2M (USD) in August 2022.
As of Aug 30, 2022, Thrombolex has raised a total of $16.8M (USD).
Thrombolex has 11 employees as of Feb 5, 2024.
Endovascular Engineering
